Benitec Biopharma Inc.
| NASDAQ: BNTC | Healthcare / Biotechnology / USA |
| 3.22 | +0.0400 | +1.26% | Vol 10.93K | 1Y Perf 1 478.95% |
| Dec 1st, 2023 15:59 DELAYED |
| BID | 3.01 | ASK | 3.29 | ||
| Open | 3.27 | Previous Close | 3.18 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 4.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 24.22 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★ 51.29 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 37.68 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 19.02 | Earnings Rating | Neutral | |
| Market Cap | 8.28M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.24 | |
| Beta | 0.98 |
Today's Price Range 3.173.43 | 52W Range 1.869.01 | 5 Year PE Ratio Range -74.30118.20 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.63% | ||
| 1 Month | -10.42% | ||
| 3 Months | 11.19% | ||
| 6 Months | 1 172.51% | ||
| 1 Year | 1 478.95% | ||
| 3 Years | 11.19% | ||
| 5 Years | -89.71% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -24.06 | |||
ROE last 12 Months | -131.71 | |||
ROA (5Y Avg) | -33.28 | |||
ROA last 12 Months | -109.89 | |||
ROC (5Y Avg) | -30.64 | |||
ROC last 12 Months | -114.60 | |||
Return on invested Capital Q | -53.36 | |||
Return on invested Capital Y | -83.73 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 4.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 0.36 | ||||
| 110.64 | ||||
| 2.80 | ||||
| -0.40 | ||||
| -1.77 | ||||
| 0.36 | ||||
| 0.52 | ||||
| -10 552 500.00 | ||||
| Forward PE | -8.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.50 | ||||
| 5.70 | ||||
| 0.03 | ||||
| 0.05 | ||||
| -455.40 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 88.50 | ||||
| -24 953.40 | ||||
| -24 416.40 | ||||
| -3 976.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 48.00K | ||||
| 0.00 | ||||
| -40.90 | ||||
| -39.68 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | - | -0.16 | - |
| Q02 2023 | - | -40.00 | - |
| Q01 2023 | -0.12 | -0.47 | -291.67 |
| Q04 2022 | -0.28 | -0.62 | -121.43 |
| Q03 2022 | -0.44 | -0.40 | 9.09 |
| Q02 2022 | - | -117.99 | - |
| Q01 2022 | - | -0.62 | - |
| Q04 2021 | - | -60.98 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.15 | -25.00 | Negative |
| 3/2023 QR | -0.15 | -25.00 | Negative |
| 6/2023 FY | -0.74 | -54.17 | Negative |
| 6/2024 FY | -0.39 | -50.00 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 10.93K |
| Shares Outstanding | 2.57K |
| Shares Float | 2.00M |
| Trades Count | 96 |
| Dollar Volume | 35.76K |
| Avg. Volume | 11.65K |
| Avg. Weekly Volume | 9.08K |
| Avg. Monthly Volume | 8.21K |
| Avg. Quarterly Volume | 17.65K |
Benitec Biopharma Inc. (NASDAQ: BNTC) stock closed at 3.18 per share at the end of the most recent trading day (a 3.92% change compared to the prior day closing price) with a volume of 7.34K shares and market capitalization of 8.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 14 people. Benitec Biopharma Inc. CEO is Jerel A. Banks.
The one-year performance of Benitec Biopharma Inc. stock is 1478.95%, while year-to-date (YTD) performance is 1770.59%. BNTC stock has a five-year performance of -89.71%. Its 52-week range is between 1.86 and 9.01, which gives BNTC stock a 52-week price range ratio of 19.02%
Benitec Biopharma Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 110.64, a price to cashflow ratio of 2.80, a PEG ratio of -, a ROA of -109.89%, a ROC of -114.60% and a ROE of -131.71%. The company’s profit margin is -%, its EBITDA margin is -24 416.40%, and its revenue ttm is $48.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Benitec Biopharma Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Benitec Biopharma Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Benitec Biopharma Inc. is Strong Buy (1), with a target price of $4, which is +24.22% compared to the current price. The earnings rating for Benitec Biopharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Benitec Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Benitec Biopharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.54, ATR14 : 0.28, CCI20 : -102.61, Chaikin Money Flow : -0.25, MACD : -0.06, Money Flow Index : 36.05, ROC : -7.02, RSI : 44.61, STOCH (14,3) : 15.85, STOCH RSI : 0.25, UO : 27.25, Williams %R : -84.15), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Benitec Biopharma Inc. in the last 12-months were:
Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV).
CEO: Jerel A. Banks
Telephone: +1 510 780-0819
Address: 3940 Trust Way, Hayward 94545, CA, US
Number of employees: 14
